TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07315360: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTIO

Sponsor: Pfizer · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 28 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,837,920

Rescue Site Savings

+$2,528,512

Unlock Full NCT07315360 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07315360 Rescue Dossier →